Cash Flow from Financial Activities: The net amount of cash transactions used in funding activities.
Innate Pharma SA (IPHYF) had Cash Flow from Financial Activities of $11.89M for the most recently reported fiscal quarter, ending 2025-06-30.
| Income Statement Financials | |
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
| Balance Sheet Financials | |
$73.76M |
|
$5.62M |
|
$31.74M |
|
$105.50M |
|
$33.40M |
|
-- |
|
$66.26M |
|
$99.66M |
|
$5.84M |
|
$5.84M |
|
$5.84M |
|
92.18M |
|
| Cash Flow Statement Financials | |
$-35.38M |
|
$7.92M |
|
|
Cash Flow from Financial Activities |
$11.89M |
$75.37M |
|
$60.96M |
|
$-14.41M |
|
$1.76M |
|
-- |
|
-- |
|
| Fundamental Metrics & Ratios | |
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|